Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Pulmonary Medicine

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Lung functions among patients with pulmonary tuberculosis in Dar es Salaam – a cross-sectional study

  • Mohamed Manji1Email author,
  • Grace Shayo1,
  • Simon Mamuya2,
  • Rose Mpembeni3,
  • Ahmed Jusabani4 and
  • Ferdinand Mugusi1
BMC Pulmonary MedicineBMC series – open, inclusive and trusted201616:58

https://doi.org/10.1186/s12890-016-0213-5

Received: 10 November 2015

Accepted: 4 April 2016

Published: 23 April 2016

Abstract

Background

Approximately 40–60 % of patients remain sufferers of sequela of obstructive, restrictive or mixed patterns of lung disease despite treatment for pulmonary tuberculosis (PTB). The prevalence of these abnormalities in Tanzania remains unknown.

Methods

A descriptive cross-sectional study was carried out among 501 patients with PTB who had completed at least 20 weeks of treatment. These underwent spirometry and their lung functions were classified as normal or abnormal (obstructive, restrictive or mixed). Logistic regression models were used to explore factors associated with abnormal lung functions.

Results

Abnormal lung functions were present in 371 (74 %) patients. There were 210 (42 %) patients with obstructive, 65 (13 %) patients with restrictive and 96 (19 %) patients with mixed patterns respectively. Significant factors associated with abnormal lung functions included recurrent PTB (Adj OR 2.8, CI 1.274 - 6.106), Human Immunodeficiency Virus (HIV) negative status (Adj OR 1.7, CI 1.055 - 2.583), age more than 40 years (Adj OR 1.7, CI 1.080 - 2.804) and male sex (Adj OR 1.7, CI 1.123 - 2.614).

Conclusion

The prevalence of abnormal lung functions is high and it is associated with male sex, age older than 40 years, recurrent PTB and HIV negative status.

Keywords

SpirometryTB sequlaeObstructionRestriction

Background

Tuberculosis (TB) is among the top infectious causes of death worldwide [1]. Patients with treated TB may remain lifelong sufferers of disabling sequelae of the disease which subsequently impair their quality of life [2]. Many studies have shown that partially treated pulmonary tuberculosis can result in airflow obstruction [37]. Studies with longer follow-up have revealed that a large percentage of patients with treated pulmonary tuberculosis show signs of permanent airflow obstruction or restrictive impairment [811]. Post tuberculosis pulmonary impairment, therefore has emerged as a distinct clinical entity [12].

With 170,000 reported TB cases in the year 2014, Tanzania ranked the 18th among the 22 WHO high TB burdened countries in the world [13]. The prevalence of bacteriologically confirmed TB in Tanzania was 295 per 100,000 adults in the year 2010 [14]. Despite this high burden of TB, there is no formal evidence of post tuberculous pulmonary abnormalities from Tanzania. Factors associated with these complications or factors that may predict long term residual abnormalities in such patients has also been poorly addressed. This study was aimed at determining the prevalence and the factors associated with these abnormalities.

Methods

Study design and population

We conducted a health facility-based descriptive cross sectional study between July and December 2014 in Temeke municipality, the largest of three municipalities in Dar es Salaam city. Two busy TB clinics in this municipality, the Temeke municipal hospital and the Mbagala rangi tatu health centre, were chosen. The target population was patients with pulmonary tuberculosis (PTB), both sputum smear positive and smear negative TB regardless of their HIV status. Eligible patients were aged 18 years or older, had attended the clinic and completed at least 20 of the 24 weeks of anti TB treatment. Prior research has shown that peak lung function loss in patients with TB occurs within 6 months of diagnosis [8]. We enrolled patients who had completed 20 of the 24 weeks of anti TB treatment (i.e. 5 months), since most of these subjects would have achieved a microbiological cure, and that such timing would enable identification of sequel of disease without considering active disease. This timing was also reasonable in allowing data collection for a maximal number of subjects given that patients are discharged from the clinic at 6 months after which it would be difficult to access them. Participants were enrolled in a consecutive manner. The exclusion criteria were participants who had preexisting asthma or COPD, paraplegia, heart failure, stroke, extra pulmonary tuberculosis, contraindications to spirometry (e.g. recent surgery, myocardial infarction, vertigo, vomiting), spine deformities (kyphosis, scoliosis), chest deformities, and pregnancy.

A total of 501 participants were enrolled in the study (Fig. 1). All participants gave consent for participation. Ethical clearance for conducting the study was obtained from the Muhimbili University of Health and Allied Sciences (MUHAS) institutional review board.
Fig. 1

Flow diagram for recruitment into the study

Data collection

Evaluations were incorporated into routine TB clinic visits. A clinical record form (CRF) was used for data collection. A thorough history and physical examination was performed for each participant and recorded on the CRF. The modified Medical research council dyspnea scale was used to assess their functional status [15]. The patients TB02 treatment card was used to obtain other relevant information including duration on anti TB treatment, serostatus for HIV and whether the PTB was smear negative or positive for acid fast bacilli (AFB) at diagnosis. This information was filled in the CRF. A digital weighing scale (OMRON) was used to measure body weight in kilograms (kg). Weight was measured in erect position wearing only light clothing and without shoes. Height was measured in centimeters using meter rods. Waist circumference was measured using a tape measure midway between the lower rib cage margin and the anterior superior iliac spine. Mid upper arm circumference (MUAC) was measured with a tape measure midway between the tip of the shoulder (the acromion) and the tip of the elbow (olecranon process).

This was followed by spirometry by means of the ndd EasyOne™ spirometer (manufactured by ndd Medizintechnik (Switzerland)). The EasyOne™ spirometer complies with the 2005 ATS/ERS spirometry standards. The spirometer does not need daily calibration [1618]. It has been used in several studies before both locally and internationally [1922]. Thus pre testing of the tool was not performed. The device is portable and not affected by environmental conditions. Precautionary measures in using the spirometer included the use of disposable mouthpiece (spirette) per participant to avoid cross contamination. Spirometry was performed in a vacant area with open sunlight and face masks and gloves were used to protect the investigator/assistants.

The forced expiratory maneuvers, the within and between maneuver evaluation for acceptability as well as test result selection were in accordance with the ATS/ERS guidelines [23]. Spirometry was performed in the standing position. The forced expiratory maneuvers were explained in local language by trained assistants (3 doctors and 1 nurse) to the participants before they underwent spirometry. Spirometry was performed without a nose clip owing to the results of a pilot study among 25 patients prior to this research that observed that patients were uncomfortable when nose clips were used during spirometry. Furthermore, a nose clip is recommended, but not a compulsory requirement for spirometry [23] and other studies have not shown significant differences in results among users and non-users of nose clips [24, 25]. Disposable mouthpieces (spirettes) were discarded after individual use. Parameters measured included forced expiratory volume in one second (FEV1) and the forced vital capacity (FVC). The highest FEV1 and FVC from three acceptable maneuvers were used for further comparison and analysis. The FEV1: FVC% was then calculated from these.

Data analysis

The lung functions were categorized into normal, obstruction, restriction and mixed patterns of lung disease according to the algorithm from the National Lung Health Education Program (NLHEP) [26].

The predicted values were derived from regression equations for healthy Tanzanian adults [22]. To compare the observed and predicted lung functions, we used the percentage of predicted values (the ratio of observed to predicted values times 100) for FVC (FVC %) and FEV1 (FEV1%). Severity for obstruction and restriction were graded according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) [27] and the American Thoracic Society/European Respiratory Society (ATS/ERS) task force recommendations [28] respectively.

Data was analyzed using SPSS (version 15.0) statistical software. Means ± standard deviation (SD) and proportions were calculated for continuous and categorical data respectively. Median and interquartile range (IQR) was used for non-normally distributed numerical data. The Chi square test and t-test were used to determine associations between variables. If more than 20 % of the cells had an expected frequency of <5, Fischer’s exact test was used instead.

Logistic regression was done to determine predictors of abnormal lung function. The dependent variable was lung function which was reported as normal or abnormal. The independent variables that were run in multivariate models were those that had a p value of < 0.2 in univariate analysis. These included age, sex, level of education, Modified Medical Research Council Dyspnea Score (MMRC Score), smoking status, sputum smear status at diagnosis (positive or negative), TB episode number (first episode or recurrent), duration from symptoms to diagnosis of TB, HIV serostatus (positive or negative) and CD4 counts. Statistically significance was achieved when p < 0.05.

Results

Study population

There were a total of 501 participants in the study (Fig. 1). Males constituted 60.5 % (303/501) of the study participants. More than 60 % (326/501) of participants were aged 40 years or younger. Majority were married or cohabiting (52.5 %) (263/501), had attained primary level education (65.9 %) (330/501) and were domestic workers (34.1 %) (171/501). Approximately 29.3 % (147/501) were ever smokers with a median of 2.5 pack years. With respect to their clinical characteristics, approximately 54.3 % (272/501) had smear positive pulmonary TB and 90.1 % (245/272) of these had converted to smear negative at 2 months of treatment. Majority (85 %) (426/501) of the patients had presented with a first episode of TB. The median time from first symptom presentation to TB diagnosis was 30 days. Approximately 30 % (152/501) of the population was HIV co-infected. Approximately 46 % (70/152) of the patients had CD4+ cell count <200cells/μL. Majority (81 %) (407/501) had good functional scores (1 to 2) for dyspnea as reported by the MMRC score (Table 1). The mean FEV1, FVC and FEV1: FVC% were 1.83 ± 0.75, 2.95 ± 1.11 and 63.02 ± 17.99 respectively.
Table 1

Sociodemographic and clinical characteristics of participants

Characteristics (N = 501)

Frequency

Percent (%)

Age Groups (years)

 18–30

166

33.1

 31–40

160

31.9

 41–50

96

19.2

 51–60

42

8.4

 >60

37

7.4

Sex

 Male

303

60.5

 Female

198

39.5

Marital Status

 Single

169

33.7

 Married/Cohabiting

263

52.5

 Divorced/Widowed

69

13.8

Education

 No Formal

62

12.4

 Primary

330

65.9

 Secondary

84

16.8

 Post-Secondary

25

5.0

Occupation

 Agriculture

19

3.8

 Domestic

171

34.1

 Industrial

64

12.8

 Office

119

23.8

 Other

128

25.5

MMRC score

 1–2

407

81.2

 3–5

94

18.8

Cigarette smoking

  

 Never smokers

354

70.7

 Ever Smokers

147

29.3

 Smoking Pack Years (Median (IQR))

2.5 (5.3)

 

Smear for Acid Fast Bacilli

  

 Positive

272

54.3

 Negative

229

45.7

Time to Negative Sputum Conversion (months)(n=272)

  

 Smear Negative at 2 Months

245

90.1

 Smear Positive at 2 Months

27

9.9

TB Episode

  

 First

426

85.0

 Recurrent

75

15.0

Duration to TB diagnosis (months)

  

 ≤1 Month

275

54.9

 >1 Month

226

45.1

HIV Status

  

 Positive

152

30.3

 Negative

349

69.7

CD4 count (n = 152)

  

 <200

70

46.2

 200–350

50

33.0

 >350

32

20.9

MMRC Score Modified Medical Research Council Dyspnea Score, BMI Body Mass Index, IQR Interquartile range

Prevalence and severity of abnormal lung functions

The overall prevalence of lung function abnormalities was 74 % (371/501). Majority was due to obstruction (42 %) (210/501) followed by mixed (19 %) (96/501) and restrictive (13 %) (65/501) abnormalities. Approximately 73 % (48/65) of patients with restrictive dysfunction has mild to moderate severity. Approximately 79 % (166/210) of patients with obstructive dysfunction had mild to moderate severity (Fig. 2).
Fig. 2

Prevalence and severity of abnormal lung functions. Pie charts showing the prevalence of the different types of lung function abnormalities (large pie chart, N = 501). The smaller pie charts show the severity of patients who had restrictive (small upper, n = 65) and obstructive abnormalities (small lower, n = 210)

Factors associated with abnormal lung functions

Patients who were aged 40 years or younger were less likely to present with abnormal lung functions (69.9 %) compared to those older than 40 years (81.7 %), p = 0.004. Abnormal lung function was more prevalent among males (78.9 %) than among females (66.7 %) (p = 0.002). However more males developed restrictive (p = 0.034) and mixed (p < 0.001) abnormalities while more females developed obstruction (p < 0.001) (Table 2). As far as clinical characteristics are concerned, higher MMRC scores were significantly associated with any abnormality (84 % for scores 3–5 vs 71.7 % for score 1–2) (p = 0.013). A similar finding was seen for mixed abnormalities (p = 0.009). However lower scores were significantly more associated with obstruction (p = 0.04). Patients who had more than 5 pack years of smoking had significantly higher obstructive abnormalities than those who had smoked for less than 5 pack years (73.3 % vs. 41.9 %) (p =0.005). Patients with recurrent TB were also more likely to have abnormal lung functions compared to those with a first episode of TB (89.3 % vs 71.4 %) (p = 0.001). Also HIV negative patients constituted significantly greater percentage of individuals with abnormal lung functions (77.1 %) compared to HIV infected patients (67.1 %) (p = 0.019). This relationship was also true for mixed lung disease (p = 0.012). However obstructive dysfunction was more common in HIV infected (66.7 %) than in HIV negative patients (52.4 %) (p = 0.014) (Table 3).
Table 2

Sociodemographic factors associated with abnormal lung functions

Characteristics

Total

Any Abnormality

P

Obstructive

P

Restrictive

P

Mixed

P

Age groups (number, %)

 ≤40 years

326

228

69.9 %

0.004*

121

53.1 %

0.132*

46

20.2 %

0.163*

61

26.8 %

0.715*

 >40 years

175

143

81.7 %

 

88

61.5 %

 

20

14.0 %

 

35

24.5 %

 

Sex (number, %)

             

 Males

303

239

78.9 %

0.003*

112

46.9 %

<0.001*

50

20.9 %

0.034*

77

32.2 %

<0.001*

 Female

198

132

66.7 %

 

97

73.5 %

 

16

12.1 %

 

19

14.4 %

 

Marital Status (number, %)

 Single

169

120

71.0 %

0.432

64

53.3 %

0.679

23

19.2 %

0.723

33

27.5 %

0.874

 Married/Cohabiting

263

201

76.4 %

 

115

57.2 %

 

36

17.9 %

 

50

24.9 %

 

 Divorced/W idowed

69

50

72.5 %

 

30

60.0 %

 

7

14.0 %

 

13

26.0 %

 

Education (number, %)

 No Formal Education

62

47

75.8 %

0.080

29

61.7 %

0.063

7

14.9 %

0.912

11

23.4 %

0.036

 Primary Education

330

249

75.5 %

 

148

59.4 %

 

45

18.1 %

 

56

22.5 %

 

 Secondary Education

84

62

73.8 %

 

26

41.9 %

 

11

17.7 %

 

25

40.3 %

 

 Post-Secondary Education

25

13

52.0 %

 

6

46.2 %

 

3

23.1 %

 

4

30.8 %

 

Occupation (number, %)

 Agriculture

19

18

94.7 %

0.05

11

61.1 %

0.005

1

5.6 %

0.236

6

33.3 %

0.013

 Domestic

171

119

69.6 %

 

81

68.1 %

 

19

16.0 %

 

19

16.0 %

 

 Industrial

64

44

68.8 %

 

16

36.4 %

 

10

22.7 %

 

18

40.9 %

 

 Office

119

96

80.7 %

 

53

55.2 %

 

14

14.6 %

 

29

30.2 %

 

 Other

128

94

73.4 %

 

48

51.1 %

 

22

23.4 %

 

24

25.5 %

 

* fishers exact

Table 3

Clinical factors associated with abnormal lung functions

Characteristics

Total

Any Abnormality

P

Obstructive

P

Restrictive

P

 

Mixed

P

MMRC score (number, %)

 1–2

407

292

71.7 %

0.013*

173

59.2 %

0.04*

53

18.2 %

0.868*

66

22.6 %

0.00

 3–5

94

79

84 %

 

36

45.6 %

 

13

16.5 %

 

30

38.0 %

9*

Cigarette smoking (number, %)

 Never smokers

354

255

72.0 %

0.118*

151

59.2 %

0.114*

49

19.2 %

0.309*

55

21.6 %

0.00

 Ever Smokers

147

116

78.9 %

 

58

50.0 %

 

17

14.7 %

 

41

35.3 %

7*

Smoking Pack Years (number, %) (n=147)

 ≤5

107

86

80.4 %

0.5*

36

41.9 %

0.005*

16

18.6 %

0.068*

34

39.5 %

0.12

 >5

40

30

75.0 %

 

22

73.3 %

 

1

3.3 %

 

7

23.3 %

6*

Smear for Acid Fast Bacilli (number, %)

 Smear Positive

272

198

72.8 %

0.54*

110

55.6 %

0.754*

31

15.7 %

0.278*

57

28.8 %

0.19

 Smear Negative

229

173

75.5 %

 

99

57.2 %

 

35

20.2 %

 

39

22.5 %

2*

Time to Negative Sputum Conversion (number, %)

 Smear Positive at 2 Months

27

19

70.4 %

0.82*

11

57.9 %

1.0*

3

15.8 %

1.0*

 

26.3 %

1.0*

 Smear Negative at 2 Months

245

179

73.1 %

 

99

55.3 %

 

28

15.6 %

  

29.1 %

 

TB Episode Number (number, %)

 First

426

304

71.4 %

0.001*

171

56.3 %

1.0*

59

19.4 %

0.111*

74

24.3 %

0.16

 Recurrent

75

67

89.3 %

 

38

56.7 %

 

7

10.4 %

 

22

32.8 %

6*

Duration to TB diagnosis (mo) (number, %)

 ≤1 Month

275

207

75.3

0.539*

117

56.5 %

1.0*

40

19.3 %

0.414*

50

24.2 %

0.40

 >1 Month

226

164

72.6

 

92

56.1 %

 

26

15.9 %

 

46

28.0 %

6*

HIV Status (number, %)

 HIV Positive

152

102

67.1 %

0.026*

68

66.7 %

0.014*

17

16.7 %

0.764*

17

16.7 %

0.01

 HIV Negative

349

269

77.1 %

 

141

52.4 %

 

49

18.2 %

 

79

29.4 %

2*

 CD4 count (Median (IQR))

 

202.50 (210)

  

192.5 (225)

 

200 (156)

 

260(167)

 

* fishers exact, MMRC score Modified Medical Research Council Dyspnea score, BMI Body Mass Index, IQR Interquartile range

In multivariate analysis significant predictors for any abnormality were age > 40 years (Adj OR 1.740, CI 1.080 - 2.804), male sex (Adj OR 1.713, CI 1.123 - 2.614), TB recurence (Adj OR 2.789, CI 1.274 - 6.106) and HIV negative status (Adj OR 1.651, CI 1.055 - 2.583) (Table 4).
Table 4

Logistic regression analysis of sociodemographic and clinical parameters

Characteristic (n = 501)

Comparison

OR

95 % CI

P

Adj OR

95 % CI

P

Age >40 years

≤40 years

1.921

1.224–3.014

0.005

1.740

1.080–2.804

0.023

Male

Female

1.867

1.24 -2.797

0.002

1.713

1.123–2.614

0.013

Any Formal Education

No Formal

0.899

0.944–8.087

0.736

-

-

-

MMRC score 3–5

MMRC ≤2

2.074

1.147 -3.752

0.016

1.786

0.962–3.316

0.066

Ever Smoker

Never smoker

1.453

0.918–2.300

0.111

-

-

-

Smear Positive TB

Smear Negative

0.866

0.579–1.296

0.484

-

-

-

Smear Positive at 2 months

Smear negative at 2 months

0.876

.366–2.096

0.766

-

-

-

TB recurrence (Any recurrence)

1st episode

3.361

1.568–7.206

0.002

2.789

1.274–6.106

0.010

Duration to Diagnosis >1 month

≤1 months

0.869

0.582–1.297

0.492

-

-

-

HIV Negative

HIV Positive

1.648

1.082–2.510

0.020

1.651

1.055–2.583

0.028

CD4 count >350

<350

0.362

0.124–1.059

0.064

-

-

-

MMRC Score Modified Medical Research Council Dyspnea Score, Adj Adjusted

Discussion

The prevalence of abnormal lung functions of any type in this study was 74 % and the prevalence of individual patterns of impairment was 42, 13 and 19 % for obstructive, restrictive and mixed patterns of lung disease respectively. These findings indicate a huge burden of post treatment pulmonary function abnormalities in patients with pulmonary tuberculosis. It was also found that majority of patients with obstructive and restrictive abnormalities had mild to moderate severity. The findings of the present study are similar to those done elsewhere. For instance, in a study by Pasipanodya et al. (2007) in the USA, the prevalence of abnormal lung function of any type was 59 % and the prevalence of individual subtypes of impairment for obstructive, restrictive and mixed were 15, 31 and 13 % respectively [29]. While the prevalence of pulmonary impairment was higher in our study, it suffices to note that pulmonary functions are abnormal in the majority of patients upon completion of chemotherapy. This has been a consistent finding in studies done in other parts of the world [6, 9, 30].

A striking difference can be observed in the proportion of obstructive lung disease between the Pasipanodya study and the present study. The present study revealed a markedly higher proportion of patients who had obstructive lung disease (42 % vs 15 %). In some studies pulmonary infections (like childhood pneumonias, pneumocystis jirovecii, pertussis and measles) contribute up to a third of cases of obstructive airway disease [3136]. Childhood pneumonias and measles are common in Tanzania. Other studies have found that the odds of developing obstructive disease may be even higher with TB than with smoking [19, 37, 38]. Poor socioeconomic status [39] and low birth weights [40] have also been linked with the development of obstructive impairments both of which are applicable to the Tanzanian setup. For example, 9.7 % of the Tanzanian population are below the food and poverty line [41] and 13 % of Tanzanian newborns are low birth weight [42]. Therefore, a predominance of obstructive sequelae after TB may not be so surprising in this part of the world.

We have shown that patients who presented with recurrent tuberculosis had a 2.8 fold higher likelihood of developing abnormal lung functions at the end of treatment than those with a first episode of TB. Considering that Tanzania is among the high burden countries, the burden of recurrent TB is also high. Studies in other parts of the world have also shown recurrent tuberculosis to be associated with adverse spirometric outcomes. In a population wide Korean study, Lee and colleagues showed that previous TB predicted almost 3 fold higher chance of developing obstructive lung disease [43]. Another South African study of approximately 27,000 miners showed incremental rise in lung function abnormalities with the number of TB episodes (18, 27 and 35 % among first, second and third time sufferers of TB respectively) [8].

In the present study, it was found that HIV negative individuals had a 1.7 fold more likelihood of presenting with any form of lung impairment than were HIV infected patients. These findings can be explained by the fact that the mechanisms by which tuberculosis damages the lung depend extensively on cell mediated immune processes [44]. Many typical tuberculous changes may not be found in individuals who are HIV infected due to defects in their cell mediated immunity. These have been shown in studies comparing radiographic presentations of TB among HIV positive and negative individuals [45]. For example, HIV infected patients may not have typical upper lobe involvement or form typical cavities which confer significant structural alteration to the lung morphology [45]. As a result, it is likely that HIV positive patients end up with less spirometric abnormalities for lack of gross functional alteration due to relatively preserved lung parenchyma unlike their HIV negative counterparts.

The findings of this study warrant an active search among TB patients for these abnormalities. According to these results, practitioners in TB clinics can predict patients who may be at a higher risk for these impairments. Patients with recurrent tuberculosis, patients who are HIV negative, male patients and patients older than 40 years run the highest risk of these abnormalities. The tools to detect such abnormalities are fairly simple, rapid and not overly costly and there should not be a reason to miss this population who may require assistance beyond standard anti tuberculous therapy.

One may argue that these results actually make a case for an even more intensified and rapid detection of TB patients such that earlier treatment may offset the development of these sequelae. While this concept looks plausible in theory, the findings of the present study suggest otherwise. In a subgroup analysis of duration of symptoms to TB diagnosis and lung function, there was no significant difference among patients who were diagnosed and started treatment within 1 month against those who were diagnosed and started treatment later (Table 3). This relationship was also non-significant for obstructive, restrictive and mixed disease suggesting that simply having tuberculosis imparts a risk irrespective of how soon treatment is started.

The prevalence of these abnormalities among patients completing anti TB is alarmingly high. The morbidity and impairment in quality of life conferred by these sequelae is likely to be similarly high. While such data on long term morbidity is missing in Tanzania, literature from other parts of the world suggests that these sequelae confer a significant impact on everyday functioning and quality of life [2, 4648]. In fact, some studies suggest greater morbidities from the sequelae rather than from the disease itself [2, 48]. These non-communicable post tuberculous sequelae bring to light the often overlooked processes by which TB impacts quality of life. Tuberculosis therefore imposes an infectious and non-infectious burden to the healthcare infrastructure. While the infectious and microbiologic domain has received much attention in TB treatment, a lot is still left to be desired in the non-infectious sequela.

Conclusions

The magnitude of residual lung function abnormalities among patient with tuberculosis is high despite successful administration of anti TB medications. Important factors associated with abnormal lung functions include recurrent TB, HIV negative status, age more than 40 years and male sex. The findings of this study warrant an active search of these impairments among TB patients. Studies that look at the quality of life and socioeconomic impact of residual lung function abnormalities, screening strategies and treatment need to be conducted to supplement the findings of this study.

Ethics approval and consent to participate

Ethical clearance for conducting the study was obtained from the Muhimbili University of Health and Allied Sciences (MUHAS) institutional review board.

Consent for publication

Not applicable.

Availability of data and materials

The dataset supporting the conclusions of this article are stored with the Directorate of Research and Publications of the Muhimbili University of Health and Allied Sciences and can be made available upon request.

Abbreviations

Adj: 

adjusted

ATS: 

American Thoracic Society

CI: 

confidence interval

COPD: 

chronic obstructive pulmonary disease

CRF: 

clinical record form

DALYS: 

disability adjusted life years

ERS: 

European Respiratory Society

FEV1: 

forced expiratory volume in 1st second

FVC: 

forced vital capacity

HIV: 

human immunodeficiency virus

IQR: 

interquartile range

MMRC: 

modified medical research council dyspnea score

MUAC: 

mid upper arm circumference

MUHAS: 

Muhimbili University of Health and Allied Sciences

OR: 

odd’s ratio

PFT: 

pulmonary function test

PTB: 

pulmonary tuberculosis

SPSS: 

statistical package for social sciences

TB: 

tuberculosis

Declarations

Acknowledgements

We extend our gratitude to the International Clinical, Operational and Health Services Research and Training Award (ICOHRTA) for their support. The authors would like to thank all the participants and their families for their cooperation and support. We would like to extend our appreciation to Ahmad Walji, Jaffer Lalji, Alihussein Molloo and Aliabbas Molloo who worked tirelessly during data collection. We would also like to thank Vasudev Uttamsingh and Sanjoy Basak for supplying the mouthpieces for this study. We would like to thank the staff of the Temeke Municipal Hospital and the Mbagala Rangi Tatu health centre TB clinics where the study was conducted.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Internal Medicine, Muhimbili University of Health and Allied Sciences (MUHAS)
(2)
Department of Environmental Occupational Health, Muhimbili University of Health and Allied Sciences (MUHAS)
(3)
Department of Epidemiology and Biostatistics, Muhimbili University of Health and Allied Sciences (MUHAS)
(4)
Department of Radiology, The Aga Khan Hospital

References

  1. WHO. The Global Burden of Disease 2004 Update. WHO. 2008.Google Scholar
  2. Miller TL, McNabb SJN, Hilsenrath P, Pasipanodya J, Weis SE. Personal and societal health quality lost to tuberculosis. PLoS One. 2009;4:e5080.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Snider G, Doctor L, Demas T, Shaw A. Obstructive airway disease in patients with treated pulmonary tuberculosis. Am Rev Respir Dis. 1971;103(5):625–40.PubMedGoogle Scholar
  4. Birath G, Caro J, Malmberg R, Simonsson BG. Airways obstruction in pulmonary tuberculosis. Scand J Respir Dis. 1966;47:27–36.PubMedGoogle Scholar
  5. Lancaster JF, Tomashefski JF. Tuberculosis--a cause of emphysema. Am Rev Respir Dis. 1963;87:435–7.View ArticlePubMedGoogle Scholar
  6. Plit ML, Anderson R, Van Rensburg CE, Page-Shipp L, Blott JA, Fresen JL, Feldman C. Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur Respir J. 1998;12:351–6.View ArticlePubMedGoogle Scholar
  7. Simpson DG, Uschner M, Mcclement J. Respiratory function in pulmonary tuberculosis. Am Rev Respir Dis. 1963;87:1–16.PubMedGoogle Scholar
  8. Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax. 2000;55:32–8.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Willcox PA, Ferguson AD. Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir Med. 1989;83:195–8.View ArticlePubMedGoogle Scholar
  10. Krishna K, Bond S, Artvinli M, Reid KDG, McHardy GJR, Crofton JW. Pulmonary function in treated tuberculosis; a long-term follow-up. Am Rev Respir Dis. 1977;115:402–4.Google Scholar
  11. Vargha G. Fifteen year follow-up of lung function in obstructive and non-obstructive pulmonary tuberculosis. Acta Med Hung. 1983;40:271–6.PubMedGoogle Scholar
  12. Seaton A, LA Seaton D. Crofton and Douglass’s Respiratory Disease. United Kingdom: Blackwell Science; 2002.Google Scholar
  13. WHO. Global Tuberculosis Report 2015. 2015.Google Scholar
  14. The First National Tuberculosis Prevalence Survey in the United Republic of Tanzania Final Report. 2013.Google Scholar
  15. Stenton C. The MRC breathlessness scale. Occup Med (Lond). 2008;58:226–7.View ArticleGoogle Scholar
  16. Walters JAE, Wood-baker R, Walls J, Johns DP. Stability of the EasyOne ultrasonic spirometer for use in general practice. 2006. p. 306–10.Google Scholar
  17. Skloot GS, Edwards NT, Enright PL. Four-Year Calibration Stability of the EasyOne Portable Spirometer. Respir Care. 2010;55:873–7.PubMedGoogle Scholar
  18. Barr RG, Stemple KJ, Mesia-vela S, Basner C, Derk S, Henneberger P, Milton DK, Taveras B. Reproducibility and Validity of a Handheld Spirometer. Respir Care. 2008;53:433–41.PubMedPubMed CentralGoogle Scholar
  19. Hallal PC, Muin A, Lopez MV, Valdivia G, Talamo C, Pertuze J. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America ˜. Eur Respir J. 2007;30:1180–5.View ArticlePubMedGoogle Scholar
  20. Carlsen HK, Gislason T, Benediktsdottir B, Kolbeinsson TB, Hauksdottir A, Thorsteinsson T, Briem H. A survey of early health effects of the Eyjafjallajökull 2010 eruption in Iceland : a population-based study. 2012.Google Scholar
  21. Schirnhofer L, Firlei N. Using Targeted Spirometry to Reduce Non-Diagnosed Chronic Obstructive Pulmonary Disease. Respiration. 2011;81:476–82.View ArticlePubMedGoogle Scholar
  22. Knudsen TM, Mørkve ODD, Mfinanga S, Hardie JONA. Predictive equations for spirometric reference values in a healthy adult suburban population in Tanzania. Tanzan J Health Res. 2011;13:1–10.Google Scholar
  23. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.View ArticlePubMedGoogle Scholar
  24. Chavasse R, Johnson P, Francis J, Balfour-Lynn I, Rosenthal M, Bush A. To clip or not to clip? Noseclips for spirometry. Eur Respir J. 2003;21:876–8.View ArticlePubMedGoogle Scholar
  25. Newall C, McCauley T, Shakespeare J, Cooper B. Is it necessary to use a noseclip in the performance of spirometry using a wedge bellows device? Chron Respir Dis. 2007;4:53–7.View ArticlePubMedGoogle Scholar
  26. Ferguson G, Enright P, Buist A. Office spirometry for lung health assessment in adults: a consensus statement from the National Lung Health Education Program. Chest. 2000;117:1146–61.View ArticlePubMedGoogle Scholar
  27. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–76.View ArticlePubMedGoogle Scholar
  28. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, Van Der Grinten CPM , Gustafsson P, Hankinson J, Jensen R, Johnson DC, Macintyre N, Mckay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–968.View ArticlePubMedGoogle Scholar
  29. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis. Chest. 2007;131:1817–24.View ArticlePubMedGoogle Scholar
  30. Lee JH, Chang JH. Lung function in patients with chronic airflow obstruction due to tuberculous destroyed lung. Respir Med. 2003;97:1237–42.View ArticlePubMedGoogle Scholar
  31. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med. 2007;101:1163–70.View ArticlePubMedGoogle Scholar
  32. Konietzko NF, Carton RW, Leroy EP. Causes of death in patients with bronchiectasis. Am Rev Respir Dis. 1969;100:852–8.PubMedGoogle Scholar
  33. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA, Flower CD, Bilton D, Keogan MT. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1277–84.View ArticlePubMedGoogle Scholar
  34. Nicotra MB, Rivera M, Dale AM, Shepherd R, Carter R. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest. 1995;108:955–61.View ArticlePubMedGoogle Scholar
  35. Escombe AR, Moore DAJ, Gilman RH, Pan W, Navincopa M, Ticona E, Martínez C, Caviedes L, Sheen P, Gonzalez A, Noakes CJ, Friedland JS, Evans CA. The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med. 2008;5:e188.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Calderon EJ, Rivero L, Respaldiza N, Morilla R, Montes-Cano MA, Friaza V, Munoz-Lobato F, Varela JM, Medrano FJ, de la Horra C. Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease Who Are Colonized with Pneumocystis jiroveci. Clin Infect Dis. 2007;45:e17–9.View ArticlePubMedGoogle Scholar
  37. Ehrlich RI, White N, Norman R, Laubscher R, Steyn K, Lombard C, Bradshaw D. Predictors of chronic bronchitis in South African adults. Int J Tuberc Lung Dis. 2004;8:369–76.PubMedGoogle Scholar
  38. Caballero A, Torres-Duque CA, Jaramillo C, Bolívar F, Sanabria F, Osorio P, Orduz C Guevara DP, Maldonado D. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008;133:343–9.View ArticlePubMedGoogle Scholar
  39. Prescott E, Lange P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study. Eur Respir J. 1999;13:1109.View ArticlePubMedGoogle Scholar
  40. Rona RJ, Gulliford MC, Chinn S. Effects of prematurity and intrauterine growth on respiratory health and lung function in childhood. BMJ. 1993;306:817–20.View ArticlePubMedPubMed CentralGoogle Scholar
  41. National Bureau of Statistics: Tanzania in Figure 2014. Dar es Salaam. 2015.Google Scholar
  42. UNICEF. Children and Women in Tanzania. 2010.Google Scholar
  43. Lee SW, Kim YS, Kim D-S, Oh Y-M, Lee S-D. The risk of obstructive lung disease by previous pulmonary tuberculosis in a country with intermediate burden of tuberculosis. J Korean Med Sci. 2011;26:268–73.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Cooper AM. Cell mediated immune responses in Tuberculosis. Annu Rev Immunol. 2009;27:393–422.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Swaminathan S, Narendran G, Menon PA, Padmapriyadarsini C, Arunkumar N, Sudharshanam NM, Kumar SR, Chandrasekhar S, Swaminathan S. Impact of HIV Infection on Radiographic Features in Patients with Pulmonary Tuberculosis. Indian J Chest Dis Allied Sci. 2007;49:133–6.Google Scholar
  46. Weis SE, Miller TL, Hilsenrath PE, Moonan PK. Comprehensive cost description of tuberculosis care. Int J Tuberc Lung Dis. 2005;9:467.PubMedGoogle Scholar
  47. Miller TL, Reading JA, Hilsenrath P, Weis SE. What are the costs of suspected but not reported tuberculosis? Ann Epidemiol. 2006;16:777–81.View ArticlePubMedGoogle Scholar
  48. Pasipanodya JG, McNabb SJ, Hilsenrath P, Bae S, Lykens K, Vecino E, Munguia G, Miller TL, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC Public Health. 2010;10:259.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© Manji et al. 2016

Advertisement